Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Status and Forecast 2024-2031

Report ID: 920359 | Published Date: Jan 2026 | No. of Page: 109 | Base Year: 2025 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

Impact of U.S Tarrifs Analyzed 2025 

1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Corticosteroid Therapy
        1.2.3 IVIG Treatment
        1.2.4 Plasma Exchange Therapy
        1.2.5 Immunosuppressive Drug Therapy
        1.2.6 Immunomodulator Therapy
        1.2.7 Other
    1.3 Market by Application
        1.3.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital
        1.3.3 Specialist Neurology Clinic
        1.3.4 Research and Academic Laboratories
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Perspective (2016-2027)
    2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Growth Trends by Regions
        2.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Share by Regions (2016-2021)
        2.2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Regions (2022-2027)
    2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Dynamic
        2.3.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends
        2.3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers
        2.3.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Challenges
        2.3.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Revenue
        3.1.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Revenue (2016-2021)
        3.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Players (2016-2021)
    3.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue
    3.4 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio
        3.4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2020
    3.5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players Head office and Area Served
    3.6 Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Solution and Service
    3.7 Date of Enter into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Breakdown Data by Type
    4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Type (2016-2021)
    4.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Type (2022-2027)

5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Breakdown Data by Application
    5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Application (2016-2021)
    5.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2016-2027)
    6.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
        6.2.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021)
        6.2.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027)
        6.2.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2027)
    6.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
        6.3.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021)
        6.3.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027)
        6.3.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2027)
    6.4 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country
        6.4.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021)
        6.4.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2016-2027)
    7.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
        7.2.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021)
        7.2.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027)
        7.2.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2027)
    7.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
        7.3.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021)
        7.3.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027)
        7.3.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2027)
    7.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country
        7.4.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021)
        7.4.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2016-2027)
    8.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
        8.2.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2027)
    8.3 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
        8.3.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2027)
    8.4 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region
        8.4.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2016-2027)
    9.2 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
        9.2.1 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021)
        9.2.2 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027)
        9.2.3 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2027)
    9.3 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
        9.3.1 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021)
        9.3.2 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027)
        9.3.3 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2027)
    9.4 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country
        9.4.1 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021)
        9.4.2 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2016-2027)
    10.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
        10.2.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2027)
    10.3 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
        10.3.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2027)
    10.4 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country
        10.4.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Teijin Pharma
        11.1.1 Teijin Pharma Company Details
        11.1.2 Teijin Pharma Business Overview
        11.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.1.4 Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.1.5 Teijin Pharma Recent Development
    11.2 Shire
        11.2.1 Shire Company Details
        11.2.2 Shire Business Overview
        11.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.2.4 Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.2.5 Shire Recent Development
    11.3 Pfizer
        11.3.1 Pfizer Company Details
        11.3.2 Pfizer Business Overview
        11.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.3.4 Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.3.5 Pfizer Recent Development
    11.4 Octapharma
        11.4.1 Octapharma Company Details
        11.4.2 Octapharma Business Overview
        11.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.4.4 Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.4.5 Octapharma Recent Development
    11.5 Momenta Pharmaceuticals
        11.5.1 Momenta Pharmaceuticals Company Details
        11.5.2 Momenta Pharmaceuticals Business Overview
        11.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.5.4 Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.5.5 Momenta Pharmaceuticals Recent Development
    11.6 Mitsubishi Tanabe Pharma Corporation
        11.6.1 Mitsubishi Tanabe Pharma Corporation Company Details
        11.6.2 Mitsubishi Tanabe Pharma Corporation Business Overview
        11.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.6.4 Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.6.5 Mitsubishi Tanabe Pharma Corporation Recent Development
    11.7 Kedrion
        11.7.1 Kedrion Company Details
        11.7.2 Kedrion Business Overview
        11.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.7.4 Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.7.5 Kedrion Recent Development
    11.8 Grifols
        11.8.1 Grifols Company Details
        11.8.2 Grifols Business Overview
        11.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.8.4 Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.8.5 Grifols Recent Development
    11.9 CSL Behring (CSL Limited)
        11.9.1 CSL Behring (CSL Limited) Company Details
        11.9.2 CSL Behring (CSL Limited) Business Overview
        11.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.9.4 CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.9.5 CSL Behring (CSL Limited) Recent Development
    11.10 Bio Products Laboratory
        11.10.1 Bio Products Laboratory Company Details
        11.10.2 Bio Products Laboratory Business Overview
        11.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.10.4 Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.10.5 Bio Products Laboratory Recent Development
    11.11 Baxter
        11.11.1 Baxter Company Details
        11.11.2 Baxter Business Overview
        11.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.11.4 Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.11.5 Baxter Recent Development
    11.12 MedDay Pharmaceuticals
        11.12.1 MedDay Pharmaceuticals Company Details
        11.12.2 MedDay Pharmaceuticals Business Overview
        11.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.12.4 MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.12.5 MedDay Pharmaceuticals Recent Development
    11.13 GeNeuro Pharmaceuticals
        11.13.1 GeNeuro Pharmaceuticals Company Details
        11.13.2 GeNeuro Pharmaceuticals Business Overview
        11.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
        11.13.4 GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
        11.13.5 GeNeuro Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Corticosteroid Therapy
    Table 3. Key Players of IVIG Treatment
    Table 4. Key Players of Plasma Exchange Therapy
    Table 5. Key Players of Immunosuppressive Drug Therapy
    Table 6. Key Players of Immunomodulator Therapy
    Table 7. Key Players of Other
    Table 8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 9. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 10. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions (2016-2021) & (US$ Million)
    Table 11. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2016-2021)
    Table 12. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2022-2027)
    Table 14. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends
    Table 15. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers
    Table 16. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Challenges
    Table 17. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints
    Table 18. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Players (2016-2021) & (US$ Million)
    Table 19. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players (2016-2021)
    Table 20. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2020)
    Table 21. Ranking of Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies by Revenue (US$ Million) in 2020
    Table 22. Global 5 Largest Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (CR5 and HHI) & (2016-2021)
    Table 23. Key Players Headquarters and Area Served
    Table 24. Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Solution and Service
    Table 25. Date of Enter into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
    Table 28. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2016-2021)
    Table 29. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 30. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 31. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Share by Application (2016-2021) & (US$ Million)
    Table 32. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application (2016-2021)
    Table 33. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 34. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 35. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
    Table 36. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027) & (US$ Million)
    Table 37. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021) (US$ Million)
    Table 38. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027) & (US$ Million)
    Table 39. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021) & (US$ Million) 
    Table 40. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027) & (US$ Million) 
    Table 41. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
    Table 42. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027) & (US$ Million)
    Table 43. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021) (US$ Million)
    Table 44. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027) & (US$ Million)
    Table 45. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021) & (US$ Million) 
    Table 46. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027) & (US$ Million) 
    Table 47. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021) (US$ Million)
    Table 50. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027) & (US$ Million)
    Table 51. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2016-2021) & (US$ Million) 
    Table 52. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2022-2027) & (US$ Million) 
    Table 53. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
    Table 54. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027) & (US$ Million)
    Table 55. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021) (US$ Million)
    Table 56. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027) & (US$ Million)
    Table 57. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021) & (US$ Million) 
    Table 58. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027) & (US$ Million) 
    Table 59. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2016-2021) (US$ Million)
    Table 62. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2022-2027) & (US$ Million)
    Table 63. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2016-2021) & (US$ Million) 
    Table 64. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2022-2027) & (US$ Million) 
    Table 65. Teijin Pharma Company Details
    Table 66. Teijin Pharma Business Overview
    Table 67. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 68. Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 69. Teijin Pharma Recent Development
    Table 70. Shire Company Details
    Table 71. Shire Business Overview
    Table 72. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 73. Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 74. Shire Recent Development
    Table 75. Pfizer Company Details
    Table 76. Pfizer Business Overview
    Table 77. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 78. Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 79. Pfizer Recent Development
    Table 80. Octapharma Company Details
    Table 81. Octapharma Business Overview
    Table 82. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 83. Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 84. Octapharma Recent Development
    Table 85. Momenta Pharmaceuticals Company Details
    Table 86. Momenta Pharmaceuticals Business Overview
    Table 87. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 88. Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 89. Momenta Pharmaceuticals Recent Development
    Table 90. Mitsubishi Tanabe Pharma Corporation Company Details
    Table 91. Mitsubishi Tanabe Pharma Corporation Business Overview
    Table 92. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 93. Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 94. Mitsubishi Tanabe Pharma Corporation Recent Development
    Table 95. Kedrion Company Details
    Table 96. Kedrion Business Overview
    Table 97. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 98. Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 99. Kedrion Recent Development
    Table 100. Grifols Company Details
    Table 101. Grifols Business Overview
    Table 102. Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 103. Grifols Recent Development
    Table 104. CSL Behring (CSL Limited) Company Details
    Table 105. CSL Behring (CSL Limited) Business Overview
    Table 106. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 107. CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 108. CSL Behring (CSL Limited) Recent Development
    Table 109. Bio Products Laboratory Company Details
    Table 110. Bio Products Laboratory Business Overview
    Table 111. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 112. Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 113. Bio Products Laboratory Recent Development
    Table 114. Baxter Company Details
    Table 115. Baxter Business Overview
    Table 116. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 117. Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 118. Baxter Recent Development
    Table 119. MedDay Pharmaceuticals Company Details
    Table 120. MedDay Pharmaceuticals Business Overview
    Table 121. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 122. MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 123. MedDay Pharmaceuticals Recent Development
    Table 124. GeNeuro Pharmaceuticals Company Details
    Table 125. GeNeuro Pharmaceuticals Business Overview
    Table 126. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product
    Table 127. GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021) & (US$ Million)
    Table 128. GeNeuro Pharmaceuticals Recent Development
    Table 129. Research Programs/Design for This Report
    Table 130. Key Data Information from Secondary Sources
    Table 131. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type: 2020 VS 2027
    Figure 2. Corticosteroid Therapy Features
    Figure 3. IVIG Treatment Features
    Figure 4. Plasma Exchange Therapy Features
    Figure 5. Immunosuppressive Drug Therapy Features
    Figure 6. Immunomodulator Therapy Features
    Figure 7. Other Features
    Figure 8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application: 2020 VS 2027
    Figure 9. Hospital Case Studies
    Figure 10. Specialist Neurology Clinic Case Studies
    Figure 11. Research and Academic Laboratories Case Studies
    Figure 12. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Years Considered
    Figure 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 14. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 15. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions: 2020 VS 2027
    Figure 16. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2022-2027)
    Figure 17. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players in 2020
    Figure 18. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2020
    Figure 19. The Top 10 and 5 Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2020
    Figure 20. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2016-2021)
    Figure 21. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2022-2027)
    Figure 22. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2016-2027)
    Figure 24. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2016-2027)
    Figure 25. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2016-2027)
    Figure 26. United States Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2016-2027)
    Figure 30. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2016-2027)
    Figure 31. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2016-2027)
    Figure 32. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. U.K. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Nordic Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2016-2027)
    Figure 40. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2016-2027)
    Figure 41. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Region (2016-2027)
    Figure 42. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2016-2027)
    Figure 50. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2016-2027)
    Figure 51. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2016-2027)
    Figure 52. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2016-2027)
    Figure 56. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2016-2027)
    Figure 57. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2016-2027)
    Figure 58. Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 61. Teijin Pharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 62. Shire Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 63. Pfizer Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 64. Octapharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 65. Momenta Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 66. Mitsubishi Tanabe Pharma Corporation Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 67. Kedrion Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 68. Grifols Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 69. CSL Behring (CSL Limited) Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 70. Bio Products Laboratory Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 71. Baxter Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 72. MedDay Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 73. GeNeuro Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2016-2021)
    Figure 74. Bottom-up and Top-down Approaches for This Report
    Figure 75. Data Triangulation
    Figure 76. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Teijin Pharma
Shire
Pfizer
Octapharma
Momenta Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
Kedrion
Grifols
CSL Behring (CSL Limited)
Bio Products Laboratory
Baxter
MedDay Pharmaceuticals
GeNeuro Pharmaceuticals
Frequently Asked Questions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Cloud API

The Cloud API runs as middleware between systems or applications to ensure effective communicatio ... Read More

Cloud TV

Cloud TV is a software platform that virtualizes set-top box capabilities, enabling service provi ... Read More